

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Impact of Providing Future Cardiovascular Risk Based on Genetic Testing on Low-Density Lipoprotein Cholesterol in Patients with Familial Hypercholesterolemia (GenTLe-FH): A Randomized Wait-list Controlled Open-Label Trial

Short title: Impact of genetic testing on LDL-C in GenTLe-FH

Akihiro Nomura,^{1,2} MD, PhD, Hirofumi Okada², MD, PhD, Atsushi Nohara³, MD, PhD, Masaki Kawashiri⁴, MD, PhD, Masayuki Takamura², MD, PhD, Hayato Tada², MD, PhD

¹ Innovative Clinical Research Center, Kanazawa University (iCREK), Kanazawa, Japan

² Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

³ Department of Clinical Genetics, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

⁴ Department of Internal Medicine, Kaga Medical Center, Kaga, Japan

Corresponding author:

Hayato Tada, MD, PhD

Assistant Professor

Department of Cardiovascular and Internal Medicine

Kanazawa University Graduate School of Medical Sciences

13-1 Takara-machi, Kanazawa, Ishikawa, 9208641 Japan

Phone number: +81-76-265-2254

E-mail: ht240z@sa3.so-net.ne.jp

ORCID ID: 0000-0002-3357-1809

Word count:

32 **Abstract**

33 **Background and Aims:** Familial hypercholesterolemia (FH) is an autosomal dominant
34 monogenic disease characterized by high low-density lipoprotein cholesterol (LDL-C) levels.
35 Although carrying causative FH variants is associated with coronary heart disease (CHD), it
36 remains unclear whether disclosing its associated cardiovascular risk affects outcomes in
37 patients with FH. Here, we evaluated the efficacy of providing future cardiovascular risk based
38 on genetic testing in addition to a standard FH education program.

39 **Methods:** We conducted a randomized, wait-list controlled, open-label, single-center trial. In
40 the intervention group, we reported a future cardiovascular risk based on the genetic testing
41 adding to standard FH education at week 0. In the wait-list control group, we only disseminated
42 standard FH education according to the guidelines at week 0; they later received a genetic
43 testing-based cardiovascular risk assessment at week 24. The primary endpoint of this study
44 was the plasma LDL-C level at week 24.

45 **Results:** Fifty eligible patients with clinically diagnosed FH, without a history of CHD, were
46 allocated to the intervention group (n=24) or the wait-list control group (n=26). At week 24,
47 the intervention group had a significantly greater reduction in LDL-C levels than the wait-list
48 control group (mean changes, -13.1 mg/dL vs. 6.6 mg/dL; difference, -19.7 mg/dL; 95%
49 confidence interval, -34 to -5.6; p=0.009). This interventional effect was consistent with FH
50 causative variant carriers but not with non-carriers.

51 **Conclusions:** In addition to standard FH care, providing future cardiovascular risk based on
52 genetic testing can further reduce plasma LDL-C levels, particularly among FH causal variant
53 carriers.

54

55 **Registration:** Japan Registry of Clinical Trials (jRCTs04218002).

56 URL: <https://jrct.niph.go.jp/latest-detail/jRCTs042180027>

57

58 **Key words:** familial hypercholesterolemia, genetic risk disclosure, genomics, coronary disease,
59 randomized clinical trials

60

61 **Non-standard Abbreviations and Acronyms**

62	APOB	apolipoprotein B
63	BMI	body mass index
64	Bpm	beats per minutes
65	CHD	coronary heart disease
66	CI	confidence interval
67	COVID-19	coronavirus disease 19
68	CVD	cardiovascular disease
69	FH	familial hypercholesterolemia
70	LDL	low-density lipoprotein
71	LDL-C	low-density lipoprotein cholesterol
72	LDLR	low-density lipoprotein receptor
73	LDLRAP1	low-density lipoprotein receptor adaptor protein 1
74	PCSK9	proprotein convertase subtilisin/kexin type 9
75	PSQ-18	Patient Satisfaction Questionnaire Short Form

76 **Introduction**

77 Familial hypercholesterolemia (FH) is an autosomal dominant Mendelian disease, one
78 of the leading causes of premature coronary heart disease (CHD) along with life-long exposure
79 to high low-density lipoprotein (LDL) cholesterolemia.¹⁻⁶ The prevalence of patients with
80 heterozygous FH is nearly 0.2-0.5% of the general population (1 in 200-500 individuals). Major
81 FH causative genes are LDL receptor (*LDLR*), proprotein convertase subtilisin/kexin type 9
82 (*PCSK9*), and apolipoprotein B (*APOB*) and LDLR adaptor protein 1 (*LDLRAP1*, for a
83 particular case of autosomal recessive hypercholesterolemia). FH's clinical guidelines of FH
84 across the world recommend that patients with FH should be treated using lipid-lowering
85 agents at a younger age to reduce plasma LDL cholesterol (LDL-C) levels, which can prevent
86 future episodes of CHD. Therefore, it is important to diagnose FH as early as possible.⁷

87 Because FH is a monogenic disorder, genetic testing is important for a definitive
88 diagnosis.⁸ Additionally, our previous study and other studies showed that FH-related
89 pathogenic variants are significantly associated with a higher risk of CHD,^{9,10} which strongly
90 suggests that genetic testing can be used for risk stratification. However, it remains unclear
91 whether FH-related genetic testing would have a potential to affects patients' outcomes beyond
92 risk stratification. Recently, Kullo et al. reported that disclosure of CHD risk estimates with
93 polygenic risk information, which consists of multiple small-effect genome-wide common
94 genetic variations, led to lower LDL-C levels than disclosure of CHD risk based on classical
95 risk factors alone.¹¹ Thus, does providing cardiovascular risk based on FH-related genetic
96 testing also have an impact on changing outcomes in patients with FH?

97 Here, we examined whether informing future cardiovascular risk based on genetic
98 testing besides conventional FH patient education leads to reduced LDL-C levels in patients
99 with FH.

100

101 **Methods**

102 *Overall trial design*

103 This study was a randomized, wait-list controlled, open-label, single-center trial. The
104 detailed trial protocol had been published elsewhere.⁸ In brief, we performed genetic
105 counseling and informed individuals about future cardiovascular risk based on patients'
106 monogenetic testing results for the intervention group. The primary outcome was the change
107 in plasma LDL-C levels at 24 weeks from the baseline. This trial was conducted in compliance
108 with the Declaration of Helsinki, Ethical Guidelines for Medical and Health Research
109 Involving Human Subjects, and all other applicable laws and guidelines in Japan. The study
110 protocol was approved by the Institutional Review Board of Kanazawa University Hospital
111 (Kanazawa, Japan) and registered in the Japan Registry of Clinical Trials (jRCTs042180027).

112

113 *Participants*

114 We recruited patients with clinically diagnosed FH from March 2018 to March 2020
115 and followed them up until October 2021. We enrolled participants who met all the following
116 inclusion criteria: 1) age ≥ 15 years; 2) clinically diagnosed with FH according to the Japan
117 Atherosclerosis Society guidelines^{1,9} (if two of the three following criteria were met: [i] LDL-
118 C ≥ 180 mg/dL, [ii] presence of tendon xanthomas; and [iii] family history of FH or premature
119 coronary artery disease); and 3) never had a genetic test or had not returned genetic results
120 regarding FH. We also excluded participants who met any of the following exclusion criteria:
121 1) liver dysfunction (aspartate aminotransferase or alanine aminotransferase > 3 times the upper
122 normal limits); 2) renal dysfunction (serum creatinine ≥ 2.0 mg/dL); 3) immunosuppressive
123 state; 4) active cancer; 5) history of CHD including myocardial infarction, percutaneous
124 coronary intervention or coronary artery bypass graft, or coronary artery stenosis ($\geq 75\%$)

125 previously detected by coronary angiography; or 6) females expecting to be pregnant or
126 currently pregnant. Written informed consent was obtained from all trial participants.

127

128 *Screening of FH pathogenic variants*

129 We sequenced the exons of four FH-related genes (*LDLR*, *PCSK9*, *APOB*, and
130 autosomal recessive inheritance of *LDLRAP1*) using Illumina MiSeq (San Diego, USA). We
131 defined variants as FH causal when they matched any of the following criteria: a) registered as
132 pathogenic/likely pathogenic in the ClinVar database; b) minor allele frequency <1% in the
133 East Asian population with i) protein-truncating variants (nonsense, canonical splice sites, or
134 frameshift) or ii) missense variants with five *in silico* damaging scores (SIFT, PolyPhen-2
135 HDIV, PolyPhen-2 HVAR, MutationTaster2, LRT), all predicted as pathogenic;¹⁰ c) missense
136 variants reported as pathogenic in the Japanese population: *PCSK9* p.Val4Ile and
137 p.Glu32Lys;^{11,12} and d) predicted by eXome-Hidden Markov Model (XHMM) software as
138 copy number variations (large duplication/large deletion).¹³

139

140 *Intervention and wait-list control*

141 We randomized patients to either the intervention or the wait-list control groups with
142 FH using an independent web-based randomization system that included a minimization
143 algorithm balanced for age (≥ 50 years and < 50 years), sex (male and female), and causative
144 variant (positive or negative).

145 In the intervention group, we performed genetic counseling and informed the patients'
146 future cardiovascular risk based on the results of their FH-related genetic testing in addition to
147 standard FH patient education. The genetic counseling provided by a qualified physician in
148 clinical genetics consisted of the following components: a) genetic diagnosis; b) outline of FH;
149 c) examining the family history of hyperlipidemia/cardiovascular diseases; d) informing that

150 the results of genetic testing could facilitate research in this field; and e) explaining the
151 physical/mental support system in the hospital. In addition, primary cardiologists provided
152 odds ratios of future cardiovascular risk based on the presence or absence of 1) a causal genetic
153 variant and 2) a clinical sign (xanthomas and/or family history of FH) using the original
154 Japanese documents.^{8,10,14} After counseling, we set sufficient time to answer the questions from
155 the patients, confirming their level of understanding.

156 In the wait-list control group, we only disseminated standard FH patient education using
157 the Japanese booklet for FH patient education according to the FH management guideline.¹
158 After the education session, we set the time to answer the queries from the patients. After
159 evaluating the primary endpoint (24th week after randomization), the wait-list control group
160 also received their genetic testing results and future cardiovascular risks via counseling.

161 In both groups, primary cardiologists provided the standard FH education for their
162 patients. Also, primary cardiologists managed LDL cholesterol levels of their patients at their
163 own discretion according to the Japanese guideline for FH 2017 (targeting LDL cholesterol
164 level of <100 mg/dL or >50% reduction compared with an untreated level for primary
165 prevention).⁹ When adding any of lipid-lowering agents as statins, ezetimibe, or PCSK9
166 inhibitors, the patients and the physicians must agree with each other for the treatments that
167 were essential to achieve the target value of LDL cholesterol level. Moreover, the number of
168 additional treatments were compared between the intervention and the wait-list control groups.
169 Although in-person FH education was not provided outside of the scheduled outpatient clinic
170 visits, patients in both groups could receive additional counseling and/or outpatient visit when
171 patients wanted or were afraid of genetic testing regardless of the allocated groups during and
172 after the trial.

173

174 *Outcomes*

175 The primary outcome was the change in plasma LDL-C levels from baseline (week 0)
176 to week 24. Key secondary outcomes were as follows: 1) changes in plasma LDL-C levels
177 from baseline at week 48 and 2) the Patient Satisfaction Questionnaire Short Form (PSQ-18)
178 scales at weeks 24 and 48. We assessed these outcomes between the intervention and the wait-
179 list control groups or among the four groups categorized by genetic testing results (FH-related
180 causal variant, positive or negative) ([1] intervention + positive; [2] intervention + negative;
181 [3] wait-list control + positive; and [4] wait-list control + negative).

182 The PSQ-18 scale evaluates patients' inner satisfaction level for the medical care they
183 received from seven aspects.¹⁵ We used this scale because providing future cardiovascular risk
184 based on genetic testing could create stress for the patients in terms of longer consultation time,
185 higher medical costs, and more drug prescriptions to achieve the target cholesterol level,
186 particularly for the intervention group. The scale values from 1 to 5 represent the lowest to
187 highest rating for each aspect.

188

189 *Statistical analysis and early termination due to the coronavirus disease 19 (COVID-19)*
190 *pandemic*

191 We hypothesized that the estimated difference from baseline to week 24 in LDL-C
192 levels between the intervention and the wait-list control groups would be 15 mg/dL, with a
193 standard deviation of 25. In the sample size calculation, 44 patients per group were required,
194 with a two-sided α of 5% and power of 80%. We then set the drop-out rate to 10% and
195 determined that approximately 100 patients with FH were required as initially planned.⁸
196 However, we had to stop the trial enrollment in April 2020 due to the COVID-19 pandemic,
197 with a state of emergency in Japan during the enrollment period. The principal investigator and
198 sub-investigators all agreed to the decision, and we closed the trial in November 2021 after all

199 patients who agreed to enroll in the trial completed the protocol schedule before trial
200 termination.

201 We compared the outcomes between the intervention and the wait-list control groups.
202 The baseline profiles were described by mean and standard deviation, median and quantiles
203 (continuous variables), or proportion (categorical variables). In addition, we assessed the
204 primary outcome based on the intention-to-treat approach, which was compared between
205 groups using the *t*-test. Moreover, we compared the secondary endpoints between the groups
206 at each defined period using the *t*-test, Mann-Whitney *U*-test, Fisher's exact test, or linear or
207 logistic regression adjusted for appropriate covariates. A *p*-value < 0.05 was considered
208 statistically significant for the primary outcome. Statistical analyses were performed using R
209 software version 4.1.2 or above (The R Project for Statistical Computing, Vienna, Austria).

210

211 **Results**

212 **Figure 1** shows the flowchart of the trial. We recruited 53 clinically diagnosed FH
213 patients without a history of cardiovascular disease from March 2018 to March 2020 and
214 followed them up until October 2021. Of these, three patients were excluded from the trial
215 because of inappropriate eligibility (n=2) and randomization violation (n=1). The remaining
216 50 eligible patients were randomly allocated to the intervention group (n=24) or the wait-list
217 control group (n=26). In the intention-to-treat principle, we included all 50 patients for further
218 analyses. The mean age of the patients was 52 ± 16 years, 58% were female, 22% had
219 hypertension, and 8% had diabetes mellitus. Regarding FH-related profiles, 76% had Achilles
220 tendon xanthomas, 60% reported a family history of FH, and the mean plasma LDL-C level
221 was 127 ± 25 mg/dL. The number of FH-related causative genetic variant positive patients was
222 34 (68%): 31 patients had causal variants at *LDLR* gene, 1 had causal variant (p.Glu32Lys) at
223 *PCSK9* gene, and 2 had copy number variations at *LDLR* gene. We did not detect any causal

224 variants at *APOB* or *LDLRAP1*. The baseline characteristics were well balanced between the
225 intervention and the wait-list control groups (**Table 1**). Since one patient in the wait-list control
226 group refused to follow scheduled visits and laboratory tests after randomization, the study
227 investigators excluded the patient from the study and following outcome analyses.

228

229 *Primary outcome*

230 At week 24, the intervention group had a significantly greater reduction in plasma LDL-
231 C levels than the wait-list control group (mean changes from baseline, -13.1 mg/dL vs. 6.6
232 mg/dL; between-group difference, -19.7 mg/dL; 95% confidence interval [CI], -34 to -5.6;
233 $p=0.009$) (**Table 2, Figure 2**). Even when adjusted by the baseline LDL-C levels, the result
234 was consistent (adjusted difference, -18.0 mg/dL; 95% CI, -32 to -3.8; $p=0.02$).

235

236 *Secondary outcomes*

237 After the wait-list control group also received genetic testing-based future
238 cardiovascular risk assessment at week 24, the LDL-C level in the wait-list control group was
239 certainly decreased (the within-group change from week 24 to 48 was -8.0 mg/dL). In contrast,
240 the within-group change in the intervention group from week 24 to 48 was increased by 4.3
241 mg/dL, that lead to diminish the effect of LDL-C reduction in the intervention group at week
242 48 from baseline. As a result, the difference between the two groups (between-group
243 difference) from baseline to week 48 was attenuated (0.7 vs. -2.0; between-group difference,
244 2.8; 95% CI, -26 to 31; $p=0.85$) (**Table 2**).

245 **Figure 3** shows the LDL-C changes according to FH-related causative variant carrier
246 status. Among variant carriers, the intervention group also had a greater plasma LDL-C level
247 reduction than the wait-list control group at week 24 (-19.8 mg/dL vs. 2.9 mg/dL; between-
248 group difference, -22.7 mg/dL; 95% CI, -40 to -5.5; $p=0.02$). However, we could not detect

249 any significant differences between the groups for non-carriers at week 24 (2.3 mg/dL vs. 12.4
250 mg/dL; between-group difference, -10.1 mg/dL; 95% CI, -33 to 12; p=0.39).

251 Since the physicians managed LDL cholesterol levels of their patients at their own
252 discretion according to the guideline, we investigated additional treatment regimens on top of
253 the baseline lipid-lowering agents in both groups (**Table 3**). The numbers of participants
254 receiving add-on treatment during the study were 10 (42%) in the intervention group and 6
255 (23%) in the wait-list control group (chi-square test, p=0.26). Of note, 90% (9/10) in the
256 intervention group and 67% (4/6) in the wait-list control group of add-on lipid-lowering agents
257 were prescribed within 24 weeks from receiving genetic counseling and future cardiovascular
258 risk based on the genetic test. Moreover, the add-on treatments were conducted more frequent
259 in causative variant carrier group (14/16, 88%) than in non-carrier group (2/16, 12%).

260

261 *Patient satisfaction evaluation*

262 We further assessed the FH patients' satisfaction for medical care they received during
263 the study period by the PSQ-18 scale analysis (**Figure 4**). We evaluated the score changes by
264 seven aspects (general satisfaction, technical quality, interpersonal manner, communication,
265 financial aspects, time spent with doctor, and accessibility and convenience), and there were
266 no between-group differences in each aspect except in the "general satisfaction" aspect for
267 medical care. Notably, FH-related causal variant non-carriers in the intervention group were
268 less satisfied with general medical care than the wait-list control group at 24 weeks.

269

270 *Subgroup analysis*

271 **Table 4** shows the subgroup analysis results for the treatment differences in LDL-C
272 levels at week 24. There were no significant interactions in each subgroup except that age (≥ 50

273 vs. <50 years) subgroup was the only significant quantitative interaction between the
274 intervention and the wait-list control groups.

275

276 **Discussion**

277 This trial was the first randomized, wait-list controlled study to assess whether
278 disclosing the risk for future cardiovascular diseases based on genetic testing results in addition
279 to standard FH education would lead to reduced LDL-C levels in patients with FH. For the
280 primary endpoint, the intervention group showed a significantly greater reduction in plasma
281 LDL-C levels than the wait-list control group at week 24. The difference between the groups
282 was attenuated at week 48 after the wait-list control group also received future cardiovascular
283 risk assessment based on genetic testing at week 24. On the other hand, as for patient
284 satisfaction evaluation by the PSQ-18, no between-group differences were found except for the
285 general satisfaction aspect of medical care. Notably, non-carriers of FH-related causal variants
286 in the intervention group were less satisfied with general medical care than those in the wait-
287 list control group at 24 weeks.

288 The conclusions of this study are as follows. First, providing cardiovascular risk based
289 on genetic testing further reduced plasma LDL-C levels, in addition to standard FH care. One
290 of the reasons for the significant reduction effect could be that patients with FH may become
291 aware of the necessity of medication, leading to better adherence to medications and
292 achieving lifestyle modifications by themselves. However, there was a concern that the
293 LDL-C reduction might be derived from more intensive treatments based on the information
294 on genetic testing-based cardiovascular risk. Previous studies reported that providing genetic
295 testing results for primary physicians did not affect their practice because they thought
296 plasma lipid levels were simply sufficient to select treatment options for patients with FH and
297 felt little need for genetic testing.^{16,17} Nevertheless, another studies demonstrated that FH

298 genetic counseling for patients with FH might convince them of the use of more intensified
299 lipid-lowering drugs and improve medication adherence, leading to lower LDL-C levels,
300 irrespective of their treatment status.¹⁸⁻²⁰ Moreover, a genetic diagnosis itself could promote
301 the selection of more aggressive lipid-lowering drugs for primary physicians.²¹ For example,
302 the MI-GENES clinical trial, which demonstrated the effect of disclosure of CHD genetic risk
303 on LDL-C levels for patients with intermediate CHD risk, indicated that the lipid-lowering
304 effects were derived from the initiation of statin medication.²² In this study, We did not
305 observe any interactions between baseline plasma LDL-C levels and the addition of lipid-
306 lowering agents between weeks 0 and 24 (**Figure 4**). However, although non-significant, an
307 add-on lipid-lowering treatment was more frequent within 24 weeks from receiving genetic
308 counseling and future cardiovascular risk based on the genetic test (**Table 3**), which might
309 have contributed to the favorable result for LDL-C reduction in the intervention group. In
310 addition, genetic confirmation might help patients with FH reinforce a healthier diet and
311 exercise behaviors.²³ These multilateral effects could affect the LDL-C levels of FH patients
312 without a history of cardiovascular complications.

313 Second, we observed inconsistent effects of the intervention according to the variant
314 carrier status on LDL-C levels. For FH-related causal variant carriers, the change in LDL-C
315 levels in the intervention group was greater than that in the wait-list control group at week 24,
316 although this favorable change did not occur in non-carriers. As stated above, providing a
317 “positive” genetic testing result for patients may improve adherence to lipid-lowering
318 medication and permit access to specific treatments, such as the PCSK9 inhibitor.²⁴
319 Moreover, Claassen et al. showed that patients with FH who received their genetic testing
320 results had a higher perceived efficacy of lipid-lowering medication than those without.²⁵ In
321 contrast, when the FH causal variant was not identified, the negative genetic testing result
322 might provide mental relief even for at-risk patients,²⁶ which could have a literal “negative”

323 effect on non-carrier patients. Additionally, it could cause reduced compliance or motivation
324 in patients.²⁴

325 Third, although the significant LDL-C reduction was achieved after 24 weeks from
326 the disclosure of future cardiovascular risk based on genetic testing, the effect was attenuated
327 after 48 weeks of the intervention. The changes in LDL-C levels from genetic counseling
328 with providing cardiovascular risk assessment to 24 weeks were consistent in both groups (-
329 13.1 mg/dL in the intervention group and -8.0 mg/dL in the wait-list control group), whereas
330 the change in LDL-C to 48 weeks was just +0.7 mg/dL despite performing some additional
331 lipid-lowering treatments on the baseline regimen. Although a long-term health behavior
332 change was certainly challenging,^{27,28} our results implicated that the effect of our “one-time”
333 intervention in an outpatient clinic at week 0 might be effective through 6 months but could
334 be attenuated from then on.

335 Fourth, genetic counseling for FH did not make patients nervous overall, although non-
336 carriers were less satisfied with general medical care than carriers. In general, patient
337 empowerment is a potential non-clinical benefit of genetic testing. Providing a diagnosis could
338 allow the patient to improve their understanding of the disease's clinical course, treatment
339 options, and psychological control.^{26,29} Genetic testing sometimes ameliorates uncertainty,
340 stigma, and personal guilt.^{30,31} However, it could be valid only in FH patients with positive
341 genetic testing, not in those with negative genetic testing. Patients sometimes undergo genetic
342 testing because they want to confirm whether they are negative. Clinically diagnosed patients
343 with FH are at a higher risk for cardiovascular disease than patients without FH, regardless of
344 the causative variant carrier status. However, when we provide variant-negative patients with
345 less CHD risk than variant-positive FH patients, they might misunderstand the information,
346 become unexpectedly reassured, and decrease their adherence and lifestyle modification. Care
347 might be taken with these “non-carriers” to provide the current FH education strategy with

348 future cardiovascular risk assessment based on the variant-negative genetic testing results. This
349 is because the counseling provided in this study might potentially provide misinterpretation
350 and less satisfaction for medical care to “non-carriers”. Therefore, alternative counseling
351 strategies may be needed for patients with variant-negative FH.

352 The strength of this study was that it was a randomized trial to demonstrate the efficacy
353 of disclosing future cardiovascular disease risk assessment based on genetic testing results in
354 addition to standard FH education for FH patients without a history of cardiovascular disease.
355 The most important limitation of this study was that while we originally planned to enroll
356 approximately 100 FH patients in this study,⁸ we halted enrollment due to the COVID-19
357 pandemic and closed recruitment before completing the pre-specified protocol schedule.
358 Although the effect difference on LDL-C was larger than expected and we demonstrated the
359 efficacy of the intervention on LDL-C levels, this unique situation needs to be considered with
360 caution for clinical application of our findings. In addition, in terms of LDL-C levels, the mean
361 LDL-C levels at 48 weeks were still >100 mg/dL in both groups, which was above the
362 recommended lipid control threshold (<100 mg/dL) for FH patients as primary prevention.
363 Although clarifying cardiovascular risk for both FH patients and primary physicians could
364 improve the treatment quality,³² achieving the target LDL-C level (<100 mg/dL) has still been
365 a challenging goal, as the CASCADE-FH registry reported.³³ Although this study’s median
366 LDL-C level was lower than that from the registry, we need to focus on the target cholesterol
367 level to reduce the future cardiovascular risk for patients with FH as much as possible.
368 Furthermore, we could not assessed patients’ medication adherence except patient-reported
369 drug non-compliance that might affect the results.

370 In conclusion, in addition to standard FH care, providing cardiovascular risk assessment
371 based on genetic testing further reduced plasma LDL-C levels further, particularly among

372 patients with FH causal variants carriers. Meanwhile, we might be careful with the non-carriers
373 to provide this risk disclosure strategy based on the variant-negative genetic testing results.

374

375 **Acknowledgements**

376 We are very thankful to all the participants and staff regarding this trial. We also express
377 our gratitude to Mitsuyo Kusajima, Emi Tamukai, Ryogo Shimizu, Asako Kanadu, and Rika
378 Miyashita as clinical research coordinators; Kenichi Yoshimura, Hideki Ishikawa for
379 randomization and statistical assistance; Yasuhiko Imai, and Jia Yu for clinical data
380 management; and Toshinori Murayama, chairman of the Innovative Clinical Research Center,
381 Kanazawa University for supporting our clinical trial.

382

383 **Funding**

384 This trial was supported by a Clinical Research Grant from Kanazawa University
385 Hospital, JSPS KAKENHI (18K08064, 19K08553, 20H03927), the Astellas Foundation for
386 Research on Metabolic Disorders, the ONO Medical Research Foundation, the Ministry of
387 Health, Labour and Welfare of Japan (Research Grant for Rare and Intractable Diseases), and
388 the Japanese Circulation Society (Project for Genome Analysis in Cardiovascular Diseases).

389

390 **Conflict of interest**

391 The authors have no conflict of interest to disclose.

392

393 **Data availability statement**

394 The data in this trial are available from the corresponding author upon reasonable
395 request.

396 **References**

- 397 1. Harada-Shiba M, Arai H, Oikawa S, *et al.* Guidelines for the management of familial
398 hypercholesterolemia. *J Atheroscler Thromb* 2012;**19**:1043-1060. doi:
- 399 2. Gidding SS, Champagne MA, de Ferranti SD, *et al.* The Agenda for Familial
400 Hypercholesterolemia: A Scientific Statement From the American Heart Association.
401 *Circulation* 2015;**132**:2167-2192. doi: 10.1161/CIR.0000000000000297
- 402 3. Watts GF, Gidding S, Wierzbicki AS, *et al.* Integrated guidance on the care of
403 familial hypercholesterolaemia from the International FH Foundation. *Int J Cardiol*
404 2014;**171**:309-325. doi: 10.1016/j.ijcard.2013.11.025
- 405 4. Nordestgaard BG, Chapman MJ, Humphries SE, *et al.* Familial
406 hypercholesterolaemia is underdiagnosed and undertreated in the general population:
407 guidance for clinicians to prevent coronary heart disease: consensus statement of the
408 European Atherosclerosis Society. *Eur Heart J* 2013;**34**:3478-3490a. doi:
409 10.1093/eurheartj/eh273
- 410 5. Mabuchi H, Nohara A, Noguchi T, *et al.* Molecular genetic epidemiology of
411 homozygous familial hypercholesterolemia in the Hokuriku district of Japan. *Atherosclerosis*
412 2011;**214**:404-407. doi: 10.1016/j.atherosclerosis.2010.11.005
- 413 6. Versmissen J, Oosterveer DM, Yazdanpanah M, *et al.* Efficacy of statins in familial
414 hypercholesterolaemia: a long term cohort study. *BMJ* 2008;**337**:a2423. doi:
415 10.1136/bmj.a2423
- 416 7. Teramoto T, Kobayashi M, Tasaki H, *et al.* Efficacy and Safety of Alirocumab in
417 Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High
418 Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins-
419 ODYSSEY JAPAN Randomized Controlled Trial. *Circ J* 2016;**80**:1980-1987. doi:
420 10.1253/circj.CJ-16-0387
- 421 8. Nomura A, Tada H, Okada H, *et al.* Impact of genetic testing on low-density
422 lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a
423 randomised waiting list controlled open-label study protocol. *BMJ Open* 2018;**8**:e023636.
424 doi: 10.1136/bmjopen-2018-023636
- 425 9. Harada-Shiba M, Arai H, Ishigaki Y, *et al.* Guidelines for Diagnosis and Treatment of
426 Familial Hypercholesterolemia 2017. *J Atheroscler Thromb* 2018;**25**:751-770. doi:
427 10.5551/jat.CR003

- 428 10. Khera AV, Won HH, Peloso GM, *et al.* Diagnostic Yield and Clinical Utility of
429 Sequencing Familial Hypercholesterolemia Genes in Patients With Severe
430 Hypercholesterolemia. *J Am Coll Cardiol* 2016;**67**:2578-2589. doi:
431 10.1016/j.jacc.2016.03.520
- 432 11. Mabuchi H, Nohara A, Noguchi T, *et al.* Genotypic and phenotypic features in
433 homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin
434 type 9 (PCSK9) gain-of-function mutation. *Atherosclerosis* 2014;**236**:54-61. doi:
435 10.1016/j.atherosclerosis.2014.06.005
- 436 12. Ohta N, Hori M, Takahashi A, *et al.* Proprotein convertase subtilisin/kexin 9 V4I
437 variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. *J*
438 *Clin Lipidol* 2016;**10**:547-555 e545. doi: 10.1016/j.jacl.2015.12.024
- 439 13. Fromer M, Moran JL, Chambert K, *et al.* Discovery and statistical genotyping of
440 copy-number variation from whole-exome sequencing depth. *Am J Hum Genet* 2012;**91**:597-
441 607. doi: 10.1016/j.ajhg.2012.08.005
- 442 14. Tada H, Kawashiri MA, Nohara A, *et al.* Impact of clinical signs and genetic
443 diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in
444 patients with severe hypercholesterolaemia. *Eur Heart J* 2017. doi: 10.1093/eurheartj/ehx004
- 445 15. Marshall G, Hays R. The Patient Satisfaction Questionnaire
446 Short Form (PSQ-18). Santa Monica, CA: RAND Corporation; 1994. p7865.
- 447 16. Will CM, Armstrong D, Marteau TM. Genetic unexceptionalism: clinician accounts
448 of genetic testing for familial hypercholesterolaemia. *Soc Sci Med* 2010;**71**:910-917. doi:
449 10.1016/j.socscimed.2010.05.018
- 450 17. Lerner B, Marshall N, Oishi S, *et al.* The value of genetic testing: beyond clinical
451 utility. *Genet Med* 2017;**19**:763-771. doi: 10.1038/gim.2016.186
- 452 18. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ.
453 Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands.
454 *Lancet* 2001;**357**:165-168. doi: 10.1016/S0140-6736(00)03587-X
- 455 19. Leren TP. Cascade genetic screening for familial hypercholesterolemia. *Clin Genet*
456 2004;**66**:483-487. doi: 10.1111/j.1399-0004.2004.00320.x
- 457 20. Sturm AC, Knowles JW, Gidding SS, *et al.* Clinical Genetic Testing for Familial
458 Hypercholesterolemia: JACC Scientific Expert Panel. *J Am Coll Cardiol* 2018;**72**:662-680.
459 doi: 10.1016/j.jacc.2018.05.044

- 460 21. Paynter NP, Ridker PM, Chasman DI. Are Genetic Tests for Atherosclerosis Ready
461 for Routine Clinical Use? *Circ Res* 2016;**118**:607-619. doi:
462 10.1161/CIRCRESAHA.115.306360
- 463 22. Kullo IJ, Jouni H, Austin EE, *et al.* Incorporating a Genetic Risk Score Into Coronary
464 Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the
465 MI-GENES Clinical Trial). *Circulation* 2016;**133**:1181-1188. doi:
466 10.1161/CIRCULATIONAHA.115.020109
- 467 23. Hagger MS, Hardcastle SJ, Hingley C, *et al.* Predicting Self-Management Behaviors
468 in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of
469 Beliefs About Illnesses and Beliefs About Behaviors. *Int J Behav Med* 2016;**23**:282-294. doi:
470 10.1007/s12529-015-9531-x
- 471 24. Brown EE, Sturm AC, Cuchel M, *et al.* Genetic testing in dyslipidemia: A scientific
472 statement from the National Lipid Association. *J Clin Lipidol* 2020;**14**:398-413. doi:
473 10.1016/j.jacl.2020.04.011
- 474 25. Claassen L, Henneman L, van der Weijden T, Marteau TM, Timmermans DR. Being
475 at risk for cardiovascular disease: perceptions and preventive behavior in people with and
476 without a known genetic predisposition. *Psychol Health Med* 2012;**17**:511-521. doi:
477 10.1080/13548506.2011.644246
- 478 26. Severin F, Borry P, Cornel MC, *et al.* Points to consider for prioritizing clinical
479 genetic testing services: a European consensus process oriented at accountability for
480 reasonableness. *Eur J Hum Genet* 2015;**23**:729-735. doi: 10.1038/ejhg.2014.190
- 481 27. Middleton KR, Anton SD, Perri MG. Long-Term Adherence to Health Behavior
482 Change. *Am J Lifestyle Med* 2013;**7**:395-404. doi: 10.1177/1559827613488867
- 483 28. Bouton ME. Why behavior change is difficult to sustain. *Prev Med* 2014;**68**:29-36.
484 doi: 10.1016/j.ypmed.2014.06.010
- 485 29. Berberich AJ, Hegele RA. The role of genetic testing in dyslipidaemia. *Pathology*
486 2019;**51**:184-192. doi: 10.1016/j.pathol.2018.10.014
- 487 30. Senior V, Smith JA, Michie S, Marteau TM. Making sense of risk: an interpretative
488 phenomenological analysis of vulnerability to heart disease. *J Health Psychol* 2002;**7**:157-
489 168. doi: 10.1177/1359105302007002455
- 490 31. Weiner K, Durrington PN. Patients' understandings and experiences of familial
491 hypercholesterolemia. *Community Genet* 2008;**11**:273-282. doi: 10.1159/000121398

- 492 32. Jones LK, Sturm AC, Seaton TL, *et al.* Barriers, facilitators, and solutions to familial
493 hypercholesterolemia treatment. *PLoS One* 2020;**15**:e0244193. doi:
494 10.1371/journal.pone.0244193
- 495 33. deGoma EM, Ahmad ZS, O'Brien EC, *et al.* Treatment Gaps in Adults With
496 Heterozygous Familial Hypercholesterolemia in the United States: Data From the
497 CASCADE-FH Registry. *Circ Cardiovasc Genet* 2016;**9**:240-249. doi:
498 10.1161/CIRCGENETICS.116.001381
499

500 **Figure legends.**

501 **Figure 1. Trial flowchart.**

502 We enrolled 53 patients with clinically diagnosed FH and no prior coronary artery disease. Of
503 those, 50 eligible FH patients were randomly allocated to the intervention group (24 patients
504 receiving conventional FH education and future cardiovascular risk assessment based on
505 genetic testing) or the wait-list control group (26 patients receiving only conventional FH
506 education). We followed the two groups for up to 48 weeks and performed an intention-to-
507 treat analysis. The primary endpoint was the change in LDL-C levels from baseline at week
508 24. Because we handled the wait-list control group as a wait-list group, we also provided
509 future cardiovascular risk assessment based on genetic testing after evaluating the primary
510 endpoint at week 24.

511

512 **Figure 2. Low-density lipoprotein cholesterol changes from baseline.**

513 Regarding the primary endpoint at week 24, the intervention group had a significantly greater
514 reduction in plasma LDL-C level than the wait-list control group. After the wait-list control
515 group also received genetic testing-based future cardiovascular risk assessment at week 24,
516 the difference between the two groups was attenuated at week 48. *:p<0.05. Error bars
517 indicated the standard error.

518

519 **Figure 3. Low-density lipoprotein cholesterol changes from baseline by FH-related**
520 **causative variant carrier status with additional treatment information.**

521 **A.** Variant carriers (n=34). **B.** Non-carriers (n=16). Treatment icons (statin or ezetimibe, statin
522 and ezetimibe, or PCSK9 inhibitor) were placed at the time of each additional medication.
523 Among variant carriers, the intervention group also had a greater plasma LDL-C level
524 reduction than the wait-list control group at week 24. However, we could not detect any
525 apparent differences between the groups for non-carriers. Error bars indicated standard errors

526

527 **Figure 4. Changes in patient satisfaction questionnaire scale scores by groups.**

528 There were no between-group differences except in the “general satisfaction” aspect of medical
529 care. According to the general satisfaction scale results, variant non-carriers in the intervention
530 group were less satisfied with general medical care than the wait-list control group at 24 weeks.
531 *:p<0.05. Error bars indicated the standard error.

532 **Table 1.** Baseline characteristics.

	Total	Intervention	Wait-list control
N	50	24	26
Age, years	52 ± 16	54 ± 15	50 ± 17
Female, n (%)	29 (58)	13 (54)	16 (62)
Body weight, kg	64.0 [55-69]	64.0 [55-68]	64.1 [55-71]
BMI, kg/m²	23.4 [22-27]	23.7 [21-28]	23.0 [22-26]
Systolic blood pressure, mmHg	116 ± 16	116 ± 14	117 ± 17
Diastolic blood pressure, mmHg	70 ± 10	70 ± 10	70 ± 11
Heart rate, bpm	67 ± 11	66 ± 13	69 ± 9
Comorbidities, n (%)			
Hypertension	11 (22)	6 (25)	5 (19)
Diabetes mellitus	4 (8)	1 (4)	3 (12)
Current smoking	5 (10)	2 (8)	3 (12)
FH-related profile, n (%)			
Achilles tendon xanthomas	38 (76)	19 (79)	19 (73)
Family history of FH	30 (60)	12 (50)	18 (69)
Lipid-lowering agents at baseline, n (%)			
Statins	48 (96)	23 (96)	25 (96)
Ezetimibe	34 (68)	17 (71)	17 (65)
PCSK9 inhibitors	1 (2)	0	1 (4)
Genetic variants, n (%)			
Positive	34 (68)	17 (71)	17 (65)
At <i>LDLR</i> gene	31	15	16
At <i>PCSK9</i> gene	1	1	0
At <i>APOB</i> gene	0	0	0
At <i>LDLRAP1</i> gene (AR inheritance)	0	0	0
Copy number variations (at <i>LDLR</i> gene)	2	1	1
Negative	16 (32)	7 (29)	9 (35)
Lipid profiles			
Total cholesterol, mg/dL	205 ± 31	209 ± 33	200 ± 29
Triglycerides, mg/dL	100 ± 65	112 ± 74	90 ± 55
High-density lipoprotein cholesterol, mg/dL	59 ± 13	57 ± 12	60 ± 14
Low-density lipoprotein cholesterol, mg/dL	127 ± 25	133 ± 28	121 ± 21
PSQ-18 scale aspect			
General satisfaction	3.98 ± 0.62	3.96 ± 0.67	4.00 ± 0.58
Technical quality	3.99 ± 0.52	3.89 ± 0.59	4.09 ± 0.45
Interpersonal manner	4.09 ± 0.57	4.08 ± 0.62	4.10 ± 0.53
Communication	4.34 ± 0.41	4.38 ± 0.45	4.31 ± 0.38
Financial aspects	3.30 ± 0.68	3.21 ± 0.85	3.39 ± 0.48
Time spent with a doctor	3.74 ± 0.61	3.85 ± 0.65	3.64 ± 0.56
Accessibility and convenience	3.71 ± 0.49	3.73 ± 0.49	3.68 ± 0.49

533 Continuous values were expressed as mean \pm standard deviation or median (interquartile range).
534 Abbreviations: AR, autosomal recessive; BMI, body mass index; bpm, beats per minutes; FH,
535 familial hypercholesterolemia; LDLR, low-density lipoprotein receptor; PCSK9, proprotein
536 convertase subtilisin/kexin type 9; PSQ-18, Patient Satisfaction Questionnaire Short Form.
537

538 **Table 2. Within-group changes and between-group differences of LDL cholesterol**
539 **levels.**

	week 0 (baseline) vs. week 24	week 24 vs. week 48	week 0 (baseline) vs. week 48
1. All participants			
Within-group changes			
Intervention group			
LDL-C, mean change (SE)	-13.1 (6.2)	4.3 (2.6)	0.7 (11.3)
Wait-list control group			
LDL-C, mean change (SE)	6.6 (6.7)	-8.0 (7.0)	-2.0 (9.0)
Between-group differences*			
LDL-C, mean change [95% CI]	-19.7 [-33.8 to -5.6] p=0.009**	12.3 [-2.0 to 26.6] p=0.10	2.7 [-25.6 to 31.1] p=0.85
2. Causative variant positive			
Within-group changes			
Intervention group			
LDL-C, mean change (SE)	-19.8 (6.6)	6.0 (3.0)	-0.1 (15.6)
Wait-list control group			
LDL-C, mean change (SE)	2.9 (5.6)	-9.6 (11.5)	-7.7 (13.0)
Between-group differences*			
LDL-C, mean change [95% CI]	-22.7 [-39.9 to -5.5] p=0.02**	15.5 [-5.7 to 36.7] p=0.16	7.6 [-33.3 to 48.5] p=0.72
3. Causative variant negative			
Within-group changes			
Intervention group			
LDL-C, mean change (SE)	2.3 (6.5)	0.5 (4.9)	2.8 (9.1)
Wait-list control group			
LDL-C, mean change (SE)	12.4 (8.7)	-5.7 (5.1)	6.8 (11.2)
Between-group differences*			
LDL-C, mean change [95% CI]	-10.1 [-32.5 to 12.3] p=0.39	6.2 [-8.0 to 20.3] p=0.41	-3.9 [-33.4 to 25.6] p=0.80

540

541 *:P values were calculated comparing the intervention group with the wait-list control group

542 using the *t*-test. **: p<0.05.

543

544 **Table 3. Add-on treatment regimens by primary physicians during study period.**

	Intervention (n=24)	Wait-list control (n=26)
Total number of add-on treatment	10 (42%)	6 (23%)
Add-on timing		
Week 0 to week 16	9 (9/10, 90%)	2 (2/6, 33%)
At week 0	8	2
At week 8	1	0
At week 16	0	0
Week 24 to week 40	1 (1/10, 10%)	4 (4/6, 67%)
At week 24	0	3
At week 32	0	1
At week 40	1	0
Causative variant		
Carrier subgroup	9 (9/10, 90%)	5 (5/6, 83%)
Non-carrier subgroup	1 (1/10, 10%)	1 (1/6, 17%)
Add-on treatment regimen		
Statin / ezetimibe	9 (9/10, 90%)	3 (3/6, 50%)
PCSK9 inhibitor	1 (1/10, 10%)	3 (3/6, 50%)

545

546 PCSK9, proprotein convertase subtilisin/kexin type 9.


547 **Table 4.** Treatment differences in low-density lipoprotein cholesterol changes at week 24
548 between the intervention and the wait-list control groups by patient subgroups.

	Intervention	Wait-list control	Difference (95% CI)	P interaction
Age ≥50 (n=26)	-5.2	1.4	-6.6 [-20 to 7.0]	0.038
Age <50 (n=24)	-23.3	13.4	-36.7 [-62 to -11]	
Male (n=21)	-12.2	-0.4	-11.8 [-33 to 9.7]	0.41
Female (n=29)	-13.8	10.4	-24.2 [-43 to -5.0]	
BMI ≥25 (n=15)	-19.1	2.3	-21.4 [-48 to 5.1]	0.88
BMI <25 (n=35)	-10.4	8.6	-19.0 [-36 to -2.0]	
Hypertension+ (n=11)	-6.6	-0.6	-6.0 [-28 to 16]	0.30
Hypertension- (n=39)	-15.4	8.6	-24.0 [-41 to -6.7]	
Xanthomas+ (n=39)	-9.5	7.7	-17.2 [-33 to -1.1]	0.51
Xanthomas- (n=11)	-25.9	3.0	-28.9 [-58 to 0.3]	
Family history of FH+ (n=30)	-12.7	8.9	-21.5 [-39 to -3.6]	0.71
Family history of FH- (n=20)	-13.5	2.4	-15.9 [-40 to 8.2]	
Causative variant positive (n=34)	-19.8	2.9	-22.7 [-40 to -9.6]	0.40
Causative variant negative (n=16)	2.3	12.4	-10.1 [-33 to 12]	
Baseline LDL-C ≥130 (n=21)	-25.8	3.4	-29.2 [-54 to -4.7]	0.24
Baseline LDL-C <130 (n=29)	-3.3	9.1	-12.4 [-27 to 2.6]	
Adding lipid-lowering agents at week 0 to 16+ (n=11)	-20.4	5.4	-25.8 [-80 to 28]	0.72
Adding lipid-lowering agents at week 0 to 16- (n=39)	-9.2	6.7	-15.9 [-32 to 0.1]	

549

550 Abbreviations: BMI, body mass index; CI, confidence interval; FH, familial
551 hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol.

552 **Figure 1.** Trial flowchart.




553


554

555 **Figure 2.** Low-density lipoprotein cholesterol changes from baseline.

556



557 **Figure 3.** Low-density lipoprotein cholesterol changes from baseline by FH-related causative
 558 variant carrier status with additional treatment information.



559

560 **Figure 4.** Changes in patient satisfaction questionnaire scale scores by groups.

56

